DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Recommendation of “Moderate Buy” by Analysts

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $12.3333.

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Monday, April 20th. Wall Street Zen raised shares of DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DMAC. Cooperman Leon G increased its stake in DiaMedica Therapeutics by 98.2% in the third quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after purchasing an additional 1,619,761 shares during the last quarter. Millennium Management LLC acquired a new position in DiaMedica Therapeutics in the third quarter valued at $8,157,000. Paragon Associates & Paragon Associates II Joint Venture increased its stake in DiaMedica Therapeutics by 34.6% in the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after purchasing an additional 225,000 shares during the last quarter. Geode Capital Management LLC increased its stake in DiaMedica Therapeutics by 7.4% in the fourth quarter. Geode Capital Management LLC now owns 764,255 shares of the company’s stock valued at $6,085,000 after purchasing an additional 52,437 shares during the last quarter. Finally, State Street Corp increased its stake in DiaMedica Therapeutics by 31.7% in the fourth quarter. State Street Corp now owns 627,771 shares of the company’s stock valued at $4,997,000 after purchasing an additional 151,188 shares during the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Stock Up 2.4%

NASDAQ DMAC opened at $5.46 on Friday. The business has a fifty day moving average of $6.14 and a 200-day moving average of $7.43. DiaMedica Therapeutics has a fifty-two week low of $3.47 and a fifty-two week high of $10.42. The stock has a market cap of $294.18 million, a price-to-earnings ratio of -7.69 and a beta of 0.97.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). As a group, analysts anticipate that DiaMedica Therapeutics will post -0.86 EPS for the current year.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.